Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call
February 06 2020 - 8:00AM
Business Wire
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical
company focused on the development and commercialization of
therapeutics using its proprietary AMPPLIFY™ mucus-penetrating
particle (MPP) Drug Delivery Technology, today announced that it
will report fourth quarter and full year 2019 financial results on
Wednesday, February 12, 2020. Management will host a conference
call and live audio webcast to discuss these results and provide a
business update at 8:00 a.m. ET.
The dial-in numbers to access the conference call are
866-300-4091 (domestic) or 703-736-7433 (international) using the
conference ID 5786176. To access a live webcast and subsequent
archived recording of the call, please visit the “Investors &
Media” section on the Kala website at http://kalarx.com/.
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the development
and commercialization of therapeutics using its proprietary
AMPPLIFY™ MPP Drug Delivery Technology, with an initial focus on
the treatment of eye diseases. Kala has applied the AMPPLIFY Drug
Delivery Technology to a corticosteroid, loteprednol etabonate
(LE), designed for ocular applications, resulting in the August
2018 FDA approval of INVELTYS® (loteprednol etabonate ophthalmic
suspension) 1% and its investigational product, EYSUVIS
(loteprednol etabonate ophthalmic suspension) 0.25%, which is being
studied for the temporary relief of the signs and symptoms of dry
eye disease.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200206005178/en/
Investors: Hannah Deresiewicz
hannah.deresiewicz@sternir.com 212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From May 2024 to Jun 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jun 2023 to Jun 2024